Streetbeat News

Analyst Ratings

CRIS

Cantor Fitzgerald analyst Alethia Young has reiterated an Overweight rating on Curis (NASDAQ:CRIS) and maintained a $3 price target.

Portfolio Pulse from Benzinga Newsdesk

September 07, 2023 | 2:41 pm

CBAY

Raymond James analyst Steven Seedhouse maintains a Strong Buy rating on CymaBay Therapeutics (NASDAQ:CBAY) and raises the price target from $17 to $33.

Portfolio Pulse from Benzinga Newsdesk

September 07, 2023 | 2:39 pm

DOCU

DocuSign, Inc. (NASDAQ:DOCU) is set to report its Q2 fiscal 2024 results on Sept. 7, 2023. Analysts predict earnings of 66 cents per share, up from 44 cents per share in the previous year, and revenue of $677.56 million, up from $622.18 million. Several analysts have revised their ratings and price targets for the company, with a range of views from 'Sell' to 'Buy'.

Portfolio Pulse from Lisa Levin

September 07, 2023 | 2:37 pm

ELF

DA Davidson analyst Linda Bolton Weiser maintains a 'Buy' rating on e.l.f. Beauty (NYSE:ELF) and raises the price target from $163 to $176.

Portfolio Pulse from Benzinga Newsdesk

September 07, 2023 | 2:37 pm

BCYC

Cantor Fitzgerald analyst Li Watsek has reiterated an Overweight rating on Bicycle Therapeutics (NASDAQ:BCYC) and maintained a $65 price target.

Portfolio Pulse from Benzinga Newsdesk

September 07, 2023 | 2:35 pm

ASND

Cantor Fitzgerald analyst Li Watsek has reiterated an Overweight rating on Ascendis Pharma (NASDAQ:ASND) and maintained a price target of $152.

Portfolio Pulse from Benzinga Newsdesk

September 07, 2023 | 2:35 pm

ARVN

Cantor Fitzgerald analyst Li Watsek has reiterated an Overweight rating on Arvinas (NASDAQ:ARVN) and maintained a $70 price target.

Portfolio Pulse from Benzinga Newsdesk

September 07, 2023 | 2:34 pm

ODDITY

Shares of ODDITY are trading lower following a report on the stock from The Bear Cave.

Portfolio Pulse from Benzinga Newsdesk

September 07, 2023 | 2:34 pm

ASAN

Citigroup analyst Steven Enders has reiterated a Neutral rating on Asana (NYSE:ASAN) and lowered the price target from $26 to $24.

Portfolio Pulse from Benzinga Newsdesk

September 07, 2023 | 2:33 pm

APTO

Cantor Fitzgerald analyst Li Watsek has reiterated an Overweight rating on Aptose Biosciences (NASDAQ:APTO) and maintained a $38 price target.

Portfolio Pulse from Benzinga Newsdesk

September 07, 2023 | 2:33 pm